Fig. 4From: Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trialKaplan–Meier estimate of the overall survival for the two treatment groups. OS overall survival, CI confidence interval, HR hazard ratioBack to article page